In this live and interactive CME-certified program, an expert faculty panel will discuss surveillance and ongoing screening for HCC in the hepatology setting, early identification of patients with HCC, and new management and therapeutic options for patients diagnosed with HCC.
Presented for attendees of the 59th AASLD Annual Meeting. This is not an official function/event of the American Association for the Study of Liver Diseases.
| Event Date |
Details |
| Saturday, November 01, 2008 |
8:00 PM - 9:45 PM
Local Time
8:00 PM - 8:15 PM Registration and Reception
8:15 PM - 9:45 PM Symposium
|
Agenda
Welcome, Introduction, and Retrospective Review: Incidence, Prevalence, and Need for Novel Therapies
Program Chair: Robert G. Gish, MD
Significant Risk Factors, Surveillance Strategies, and Screening Tactics for HCC
Morris Sherman, MB BCh, PhD, FRCP(C)
Patient Case—Part 1: HCC Monitoring and Surveillance
Moderator: Robert G. Gish, MD
Faculty Panel: Al B. Benson, III, MD; Morris Sherman, MB BCh, PhD, FRCP(C); Barbara Sigler Morgan, MSN, NP
Multitargeted Tyrosine Kinase Inhibitors in HCC: Translating Scientific Knowledge and Evidence to Practice
Al B. Benson III, MD
Patient Case—Part 2: Emerging HCC Treatments: Will They Affect the Role of Hepatologists in Patient Care?
Moderator: Robert G. Gish, MD
Faculty Panel: Al B. Benson, III, MD; Morris Sherman, MB BCh, PhD, FRCP(C); Barbara Sigler Morgan, MSN, NP
Closing Comments and Postprogram Evaluation
Program Chair: Robert G. Gish, MD